Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Strategic shift from Italy to India strengthens supply chain resilience, expands capacity and enhances sustainability for the growing global UDCA market
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Highlighting KEYTRUDA & expanding cancer pipeline
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
